BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 24794403)

  • 1. Identification of novel PARP inhibitors using a cell-based TDP1 inhibitory assay in a quantitative high-throughput screening platform.
    Murai J; Marchand C; Shahane SA; Sun H; Huang R; Zhang Y; Chergui A; Ji J; Doroshow JH; Jadhav A; Takeda S; Xia M; Pommier Y
    DNA Repair (Amst); 2014 Sep; 21():177-82. PubMed ID: 24794403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tyrosyl-DNA phosphodiesterase 2 (TDP2) repairs topoisomerase 1 DNA-protein crosslinks and 3'-blocking lesions in the absence of tyrosyl-DNA phosphodiesterase 1 (TDP1).
    Tsuda M; Kitamasu K; Kumagai C; Sugiyama K; Nakano T; Ide H
    DNA Repair (Amst); 2020; 91-92():102849. PubMed ID: 32460231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis of Methoxy-, Methylenedioxy-, Hydroxy-, and Halo-Substituted Benzophenanthridinone Derivatives as DNA Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1) Inhibitors and Their Biological Activity for Drug-Resistant Cancer.
    Hu DX; Tang WL; Zhang Y; Yang H; Wang W; Agama K; Pommier Y; An LK
    J Med Chem; 2021 Jun; 64(11):7617-7629. PubMed ID: 34008967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 4-Pregnen-21-ol-3,20-dione-21-(4-bromobenzenesulfonate) (NSC 88915) and related novel steroid derivatives as tyrosyl-DNA phosphodiesterase (Tdp1) inhibitors.
    Dexheimer TS; Gediya LK; Stephen AG; Weidlich I; Antony S; Marchand C; Interthal H; Nicklaus M; Fisher RJ; Njar VC; Pommier Y
    J Med Chem; 2009 Nov; 52(22):7122-31. PubMed ID: 19883083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PARP1-TDP1 coupling for the repair of topoisomerase I-induced DNA damage.
    Das BB; Huang SY; Murai J; Rehman I; Amé JC; Sengupta S; Das SK; Majumdar P; Zhang H; Biard D; Majumder HK; Schreiber V; Pommier Y
    Nucleic Acids Res; 2014 Apr; 42(7):4435-49. PubMed ID: 24493735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Dual-Sensor-Based Screening System for In Vitro Selection of TDP1 Inhibitors.
    Jakobsen AK; Keller JG; Gonzalez M; Martin-Encinas E; Palacios F; Alonso C; Knudsen BR; Stougaard M
    Sensors (Basel); 2021 Jul; 21(14):. PubMed ID: 34300575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery, Synthesis, and Evaluation of Oxynitidine Derivatives as Dual Inhibitors of DNA Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1), and Potential Antitumor Agents.
    Zhang XR; Wang HW; Tang WL; Zhang Y; Yang H; Hu DX; Ravji A; Marchand C; Kiselev E; Ofori-Atta K; Agama K; Pommier Y; An LK
    J Med Chem; 2018 Nov; 61(22):9908-9930. PubMed ID: 30336023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and biological evaluation of indenoisoquinolines that inhibit both tyrosyl-DNA phosphodiesterase I (Tdp1) and topoisomerase I (Top1).
    Conda-Sheridan M; Reddy PV; Morrell A; Cobb BT; Marchand C; Agama K; Chergui A; Renaud A; Stephen AG; Bindu LK; Pommier Y; Cushman M
    J Med Chem; 2013 Jan; 56(1):182-200. PubMed ID: 23259865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poly(ADP-ribose) polymers regulate DNA topoisomerase I (Top1) nuclear dynamics and camptothecin sensitivity in living cells.
    Das SK; Rehman I; Ghosh A; Sengupta S; Majumdar P; Jana B; Das BB
    Nucleic Acids Res; 2016 Sep; 44(17):8363-75. PubMed ID: 27466387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitors of human tyrosyl-DNA phospodiesterase (hTdp1) developed by virtual screening using ligand-based pharmacophores.
    Weidlich IE; Dexheimer T; Marchand C; Antony S; Pommier Y; Nicklaus MC
    Bioorg Med Chem; 2010 Jan; 18(1):182-9. PubMed ID: 19963390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TDP1-independent pathways in the process and repair of TOP1-induced DNA damage.
    Zhang H; Xiong Y; Su D; Wang C; Srivastava M; Tang M; Feng X; Huang M; Chen Z; Chen J
    Nat Commun; 2022 Jul; 13(1):4240. PubMed ID: 35869071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and Biological Activities of 11- and 12-Substituted Benzophenanthridinone Derivatives as DNA Topoisomerase IB and Tyrosyl-DNA Phosphodiesterase 1 Inhibitors.
    Yang H; Qin C; Wu M; Wang FT; Wang W; Agama K; Pommier Y; Hu DX; An LK
    ChemMedChem; 2023 May; 18(10):e202200593. PubMed ID: 36932053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcriptomic Analysis of CRISPR/Cas9-Mediated PARP1-Knockout Cells under the Influence of Topotecan and TDP1 Inhibitor.
    Dyrkheeva NS; Malakhova AA; Zakharenko AL; Okorokova LS; Shtokalo DN; Pavlova SV; Medvedev SP; Zakian SM; Nushtaeva AA; Tupikin AE; Kabilov MR; Khodyreva SN; Luzina OA; Salakhutdinov NF; Lavrik OI
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a putative Tdp1 inhibitor (CD00509) by in vitro and cell-based assays.
    Dean RA; Fam HK; An J; Choi K; Shimizu Y; Jones SJ; Boerkoel CF; Interthal H; Pfeifer TA
    J Biomol Screen; 2014 Dec; 19(10):1372-82. PubMed ID: 25117203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isoeugenol is a selective potentiator of camptothecin cytotoxicity in vertebrate cells lacking TDP1.
    Elsayed W; El-Shafie L; Hassan MK; Farag MA; El-Khamisy SF
    Sci Rep; 2016 May; 6():26626. PubMed ID: 27220325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition.
    Murai J; Zhang Y; Morris J; Ji J; Takeda S; Doroshow JH; Pommier Y
    J Pharmacol Exp Ther; 2014 Jun; 349(3):408-16. PubMed ID: 24650937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tyrosyl-DNA Phosphodiesterase 1 (Tdp1) inhibitors.
    Huang SN; Pommier Y; Marchand C
    Expert Opin Ther Pat; 2011 Sep; 21(9):1285-92. PubMed ID: 21843105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of an oligonucleotide-based fluorescence assay for the identification of tyrosyl-DNA phosphodiesterase 1 (TDP1) inhibitors.
    Walker S; Meisenberg C; Bibby RA; Askwith T; Williams G; Rininsland FH; Pearl LH; Oliver AW; El-Khamisy S; Ward S; Atack JR
    Anal Biochem; 2014 Jun; 454(100):17-22. PubMed ID: 24637157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and biological evaluation of nitrated 7-, 8-, 9-, and 10-hydroxyindenoisoquinolines as potential dual topoisomerase I (Top1)-tyrosyl-DNA phosphodiesterase I (TDP1) inhibitors.
    Nguyen TX; Abdelmalak M; Marchand C; Agama K; Pommier Y; Cushman M
    J Med Chem; 2015 Apr; 58(7):3188-208. PubMed ID: 25811317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TDP1 and PARP1 deficiency are cytotoxic to rhabdomyosarcoma cells.
    Fam HK; Walton C; Mitra SA; Chowdhury M; Osborne N; Choi K; Sun G; Wong PC; O'Sullivan MJ; Turashvili G; Aparicio S; Triche TJ; Bond M; Pallen CJ; Boerkoel CF
    Mol Cancer Res; 2013 Oct; 11(10):1179-92. PubMed ID: 23913164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.